Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placeboThe safety profile of tolebrutinib was consistent with previous studies Paris, December 15, 2025. Results from the PERSEUS phase 3 study (clinical study identifier: NCT04458051) showed that tolebrutinib did not meet its primary endpo ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed Paris, December 15, 2025. Sanofi anticipates that the review process for the ongoing US regulatory review of tolebrutinib in non-relapsing secondary progressive multiple sclerosis (nrSPMS) will extend beyond the previously communicated US target acti ...

北京市贸促会党组书记、北京国际商会会长章建伟指出，举办"京品出海"系列活动的核心是为企业搭建 精准高效的对接平台，切实助力企业开拓海外市场。专委会将紧密围绕企业实际需求，成为连接政府与 市场、国内与国际的重要桥梁。 据介绍，目前副中心已被纳入全市医药健康产业"多点"优势布局，漷县镇集聚区已吸引包括4家上市企 业在内的众多创新主体落户，预计今年产值达60亿元，明年目标突破百亿元。 新京报讯(记者陈琳)近日，由北京市贸促会、北京国际商会主办的"京品出海"医药健康行业专场分享会 举办。会上，北京国际商会医药健康专业委员会正式揭牌成立，标志着北京在推动医药健康产业国际化 方面迈出关键一步。活动吸引了来自全球多地的专业机构代表及150余家国内外企业参会。 在当前全球科技革命与产业变革加速的背景下，医药健康产业已成为创新最活跃的赛道之一。推动"京 品"医药健康产品与服务开拓国际市场，是企业提升竞争力的必然选择。新成立的医药健康专业委员会 由北京医药行业协会倡议发起，联合默沙东、赛诺菲、阿斯利康、强生等25家国内外知名企业共同组 成，旨在聚焦行业国际化发展的共性需求，提供政策解读、市场对接、合规指导等全链条服务。 ...

The National Medical Products Administration (NMPA) in China has approved Sanofi SA’s (NASDAQ:SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura. • Sanofi stock is showing upward movement. Why is SNY stock advancing?With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type 1 diabetes and Sarclisa for two indications in relapsed and ...

血友病是我国首批被纳入罕见病目录的疾病之一，目前国内登记患者数约4万例。患者因先天缺乏特定 凝血因子，面临自发性或创伤后过度出血的风险，如不能很好控制，最终可导致关节损伤、变形乃至残 疾，甚至威胁生命。规范的规律替代治疗是控制出血的关键，2025年版《血友病治疗中国指南》将非因 子治疗定义为规律替代治疗（预防治疗）之一，但规范意味着患者每周需要进行2—3次预防性足剂量凝 血因子注射，每年100多次静脉注射，沉重的"针头负担"让不少患者望而却步。而对于伴抑制物的血友 病患者，为实现同样的凝血效果，注射量显著高于抑制物阴性患者。 ATLASⅢ期临床研究全球牵头研究者之一、南方医科大学南方医院血液科主任医师孙竞教授表示，首 个降低抗凝血酶创新疗法的获批，标志着中国血友病治疗真正迈入了非因子治疗的新时代。该药物通过 靶向降低抗凝血酶，重建凝血平衡，实现了对伴或不伴抑制物的12岁及以上重型血友病A/B患者的全覆 盖。其一年最少6针皮下注射，极大提高了给药便捷性和治疗依从性，彻底告别了传统因子治疗需要频 繁静脉注射的痛苦。它不仅填补了抑制物阳性患者无药可防的治疗空白，也为所有血友病患者提供了一 种更高效、更可持续的治疗新 ...

行业动态 - 两种用于慢性和急性适应症的出血性疾病治疗药物Qfitlia和Cablivi已在中国获批上市 [1] 产品信息 - Qfitlia是一种用于治疗出血性疾病的药物 [1] - Cablivi是一种用于治疗出血性疾病的药物 [1] - 两种药物均覆盖慢性与急性两种适应症 [1]

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a yearCablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medicines for rar ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a yearCablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medicines for rar ...

Sanofi (NASDAQ:SNY) is one of the best pharma stocks to invest in. Sanofi (NASDAQ:SNY) was downgraded to Neutral from Overweight by JPMorgan on December 8, with the firm also bringing the price target down to EUR 95 from EUR 105. Is Sanofi (SNY)the Best Gene-Editing Stock to Buy? The firm told investors that it is adjusting its ratings in the European pharma group to take into account its 2026 outlook. It anticipates pipeline readouts to drive sector performance, albeit if a considerable amount of the co ...

Sanofi (NASDAQ:SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has a ‘Buy’ or equivalent rating from the majority of the analysts covering the stock. With a one-year median price target of $61, the stock has an upside potential of 23.16%. According to TheFly, BofA reduced the price target on Sanofi (NASDAQ:SNY) to EUR 102 from EUR 115 on December 1, while keeping a ‘Buy’ rating on the stock. Tempus AI (NASDAQ:TEM) Acquires Ambry Genetics in $600M ...